TUMOR VACCINES

被引:23
作者
BYSTRYN, JC [1 ]
机构
[1] NYU,SCH MED,MELANOMA IMMUNOTHERAPY CLIN,NEW YORK,NY 10016
关键词
active immunotherapy; antibody; antigen; immunotherapy; melanoma; shedding; vaccine;
D O I
10.1007/BF00047590
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melanoma vaccines are an exciting and increasingly attractive immunotherapeutic approach for malignant melanoma. Vaccines can be used for patients with high risk primary melanoma and regional disease, stages in the progression of melanoma for which there is presently no treatment. They are unique in their potential to prevent cancer in high risk individuals. Multiple approaches are being followed to develop effective vaccines. It is too early to judge whether any of them effectively slow the progression of melanoma. However, it is clear that vaccines are safe to use, and that they can stimulate immune responses to melanoma in some patients. The specificity of these responses needs to be clarified, and multiple challenges remain to be overcome before effective vaccines to melanoma become available. We must first identify the antigens on melanoma that stimulate immune responses, define the immune effector mechanisms that are stimulated by vaccine immunization and identify those responsible for increasing resistance to tumor growth, devise appropriate ways of constructing vaccines that will induce such responses, and find adjuvants and/or immunodulators that will potentiate desirable immune responses. © 1990 Kluwer Academic Publishers.
引用
收藏
页码:81 / 91
页数:11
相关论文
共 47 条
  • [1] ADLER A, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P252
  • [2] NONSPECIFIC AND SPECIFIC ACTIVE IMMUNOTHERAPY IN A B-16 MURINE MELANOMA SYSTEM
    AVENT, J
    VERVAERT, C
    SEIGLER, HF
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1979, 12 (01) : 87 - 96
  • [3] BERG D, 1988, CANCER INVEST, V6, P337
  • [4] BYSTRYN J C, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P280
  • [5] BYSTRYN J-C, 1985, Journal of Dermatology (Tokyo), V12, P1
  • [6] Bystryn J-C, 1989, HUMAN TUMOR ANTIGENS, P307
  • [7] BYSTRYN JC, 1986, J BIOL RESP MODIF, V5, P211
  • [8] IMMUNOLOGY AND IMMUNOTHERAPY OF HUMAN-MALIGNANT MELANOMA
    BYSTRYN, JC
    [J]. DERMATOLOGIC CLINICS, 1985, 3 (02) : 327 - 334
  • [9] PROGNOSTIC-SIGNIFICANCE OF HYPOPIGMENTATION IN MALIGNANT-MELANOMA
    BYSTRYN, JC
    RIGEL, D
    FRIEDMAN, RJ
    KOPF, A
    [J]. ARCHIVES OF DERMATOLOGY, 1987, 123 (08) : 1053 - 1055
  • [10] BYSTRYN JC, 1981, CANCER RES, V41, P910